Afinitor
Novartis fails to sway NICE with Afinitor deal
November 26, 2010Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus
Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …
FDA approves Novartis’ Afinitor
November 1, 2010Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis
Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …
NICE poised to reject Novartis’ Afinitor
July 8, 2010Sales and Marketing Afinitor, NICE, Novartis
Novartis’ kidney cancer drug Afinitor does not offer enough benefit to patients to justify its cost, according to draft guidance …
Triple approval for Novartis in Japan
January 20, 2010Sales and Marketing Afinitor, Asia, Exforge, Galvus, Japan, Novartis, hypertension
Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced …
Afinitor approved in EU
August 6, 2009Research and Development, Sales and Marketing Afinitor, Cancer, Europe, Novartis
Novartis’ new kidney cancer drug Afinitor (everolimus) has been approved in the EU for use when products such as Sutent …
Strong prospects for Novartis cancer drug, say analysts
April 24, 2009Research and Development, Sales and Marketing Afinitor, Novartis
The FDA has approved Novartis's Afinitor for advanced renal cell carcinoma patients who have progressed after first-line Sutent or Nexavar …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
